Moreover, the ability to cause regression of brain metastases in patients with non-small cell lung cancer and EGFR mutations has been well described [14–16], suggesting that the agent does have adequate penetration into the CNS to have antitumor activity. Here, EGFR is linked to non-small cell lung carcinoma.